Cellular and Molecular Biology Program, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
Nutrition. 2021 May;85:111139. doi: 10.1016/j.nut.2021.111139. Epub 2021 Jan 7.
The aim of this study was to evaluate the effect of the dietary supplementation of an alpha- and gamma-tocopherol mixture (1:5 ratio) in the adipose tissue expansion, hepatic steatosis, and expression of inflammatory markers induced by consumption of a high-fat diet (HFD) in mice.
Male C57BL/6 J mice were fed for 12 wk and divided into the following: 1) control diet (CD; 10% fat, 20% protein, 70% carbohydrates); 2) CD + TF (CD plus alpha-tocopherol: 0.7 mg/kg/d, gamma-tocopherol: 3.5 mg/kg/d); 3) HFD (60% fat, 20% protein, 20% carbohydrates); and 4) HFD + TF (HFD plus alpha-tocopherol: 0.7 mg/kg/d, gamma-tocopherol: 3.5 mg/kg/d). General parameters, adipocyte size, liver steatosis, adipose and hepatic tumor necrosis factor-α (TNF-α) and interleukin-1 β (IL-1β) expression, hepatic nuclear factor kappa B (NF-κB), and peroxisome proliferator-activated receptor α (PPAR-α) levels were evaluated.
Tocopherol supplementation in HFD-fed mice showed a significant decrease in the body weight (19%) and adipose tissue weight (52%), adipose tissue/body weight ratio (36%), and serum triacylglycerols (56%); a 42% decrease (P < 0.05) of adipocyte size compared to HFD; attenuation of liver steatosis by decreasing (P < 0.05) lipid vesicles presence (90%) and total lipid content (75%); and downregulation of inflammatory markers (TNF-α and IL-1β), along with an upregulation of hepatic PPAR-α expression and its downstream-regulated genes (ACOX and CAT-1), and an inhibition of hepatic NF-κB activation.
The present study suggests that alpha- and gamma-tocopherol (1:5 ratio) supplementation attenuates the adipocyte enlargement, hepatic steatosis, and metabolic inflammation induced by HFD in association with PPAR-α/NF-κB modulation.
本研究旨在评估富含α-生育酚和γ-生育酚（比例为 1:5）的饮食补充剂对高脂肪饮食（HFD）诱导的脂肪组织扩张、肝脂肪变性和炎症标志物表达的影响。
雄性 C57BL/6 J 小鼠喂养 12 周，并分为以下几组：1）对照饮食（CD；10%脂肪、20%蛋白质、70%碳水化合物）；2）CD+TF（CD 加α-生育酚：0.7mg/kg/d，γ-生育酚：3.5mg/kg/d）；3）HFD（60%脂肪、20%蛋白质、20%碳水化合物）；4）HFD+TF（HFD 加α-生育酚：0.7mg/kg/d，γ-生育酚：3.5mg/kg/d）。评估一般参数、脂肪细胞大小、肝脂肪变性、脂肪组织和肝脏肿瘤坏死因子-α（TNF-α）和白细胞介素-1β（IL-1β）表达、肝核因子κB（NF-κB）和过氧化物酶体增殖物激活受体-α（PPAR-α）水平。
HFD 喂养的小鼠补充生育酚可显著降低体重（19%）和脂肪组织重量（52%）、脂肪组织/体重比（36%）和血清三酰甘油（56%）；与 HFD 相比，脂肪细胞大小降低 42%（P<0.05）；通过减少脂质泡存在（90%）和总脂质含量（75%）来减轻肝脂肪变性；下调炎症标志物（TNF-α和 IL-1β），同时上调肝 PPAR-α表达及其下游调节基因（ACOX 和 CAT-1），并抑制肝 NF-κB 激活。
本研究表明，富含α-生育酚和γ-生育酚（比例为 1:5）的饮食补充剂可减轻 HFD 诱导的脂肪细胞增大、肝脂肪变性和代谢性炎症，与 PPAR-α/NF-κB 调节有关。
